Neurotrials Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Atlanta GA United States (1997)

Organization Overview

First Clinical Trial
2010
NCT00878553
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Neurotrials | NeuroTrials Research, Atlanta GA

Active Ingredients

Drugs in Phase 2 Trials (2)

act-01 (1 trial)

zaleplon (sonata) (1 trial)

Drugs in Phase 1 Trials (1)

cyclobenzaprine (flexeril) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Sleep Initiation and Maintenance Disorders (Phase 2)

Sleep Wake Disorders (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3